🇺🇸 FDA
Pipeline program

DCC-3084, DCC-3084

DCC-3084-01-001

Phase 2 small_molecule active

Quick answer

DCC-3084, DCC-3084 for Solid tumors driven by the MAPK Pathway is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Solid tumors driven by the MAPK Pathway
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials